You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CHLORAMPHENICOL; PREDNISOLONE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for chloramphenicol; prednisolone and what is the scope of freedom to operate?

Chloramphenicol; prednisolone is the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for CHLORAMPHENICOL; PREDNISOLONE
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Clinical Trials: 1
DailyMed Link:CHLORAMPHENICOL; PREDNISOLONE at DailyMed
Recent Clinical Trials for CHLORAMPHENICOL; PREDNISOLONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fundação de Amparo à Pesquisa do Estado de São PauloPhase 4
Federal University of São PauloPhase 4

See all CHLORAMPHENICOL; PREDNISOLONE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for CHLORAMPHENICOL; PREDNISOLONE
A01AC Corticosteroids for local oral treatment
A01A STOMATOLOGICAL PREPARATIONS
A01 STOMATOLOGICAL PREPARATIONS
A Alimentary tract and metabolism
A07EA Corticosteroids acting locally
A07E INTESTINAL ANTIINFLAMMATORY AGENTS
A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A Alimentary tract and metabolism
C05AA Corticosteroids
C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05 VASOPROTECTIVES
C Cardiovascular system
D06AX Other antibiotics for topical use
D06A ANTIBIOTICS FOR TOPICAL USE
D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D Dermatologicals
D07AA Corticosteroids, weak (group I)
D07A CORTICOSTEROIDS, PLAIN
D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D Dermatologicals
D07XA Corticosteroids, weak, other combinations
D07X CORTICOSTEROIDS, OTHER COMBINATIONS
D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D Dermatologicals
D10AF Antiinfectives for treatment of acne
D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10 ANTI-ACNE PREPARATIONS
D Dermatologicals
G01AA Antibiotics
G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
G Genito-urinary system and sex hormones
H02AB Glucocorticoids
H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02 CORTICOSTEROIDS FOR SYSTEMIC USE
H Systemic hormonal preparations, excluding sex hormones and insulins
J01BA Amphenicols
J01B AMPHENICOLS
J01 ANTIBACTERIALS FOR SYSTEMIC USE
J Antiinfectives for systemic use
R01AD Corticosteroids
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01 NASAL PREPARATIONS
R Respiratory system
S01AA Antibiotics
S01A ANTIINFECTIVES
S01 OPHTHALMOLOGICALS
S Sensory organs
S01BA Corticosteroids, plain
S01B ANTIINFLAMMATORY AGENTS
S01 OPHTHALMOLOGICALS
S Sensory organs
S01CB Corticosteroids/antiinfectives/mydriatics in combination
S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
S01 OPHTHALMOLOGICALS
S Sensory organs
S02AA Antiinfectives
S02A ANTIINFECTIVES
S02 OTOLOGICALS
S Sensory organs
S02BA Corticosteroids
S02B CORTICOSTEROIDS
S02 OTOLOGICALS
S Sensory organs
S03AA Antiinfectives
S03A ANTIINFECTIVES
S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S Sensory organs
S03BA Corticosteroids
S03B CORTICOSTEROIDS
S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S Sensory organs

US Patents and Regulatory Information for CHLORAMPHENICOL; PREDNISOLONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan CHLOROPTIC-P S.O.P. chloramphenicol; prednisolone OINTMENT;OPHTHALMIC 061188-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

CHLORAMPHENICOL; PREDNISOLONE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Chloramphenicol and Prednisolone

Introduction

The pharmaceutical industry is witnessing significant growth driven by the increasing demand for effective treatments for various diseases. Two drugs that are garnering attention are chloramphenicol and prednisolone, each with its unique market dynamics and financial trajectories.

Chloramphenicol Market Dynamics

Market Growth Drivers

The chloramphenicol market is anticipated to grow at a CAGR of 4-6% over the next five years, driven by several key factors:

  • Increasing Bacterial Infections: The rise in bacterial infections, particularly in densely populated areas of the Asia-Pacific region, Africa, and Latin America, is a major driver. Chloramphenicol is a broad-spectrum antibiotic effective against serious bacterial infections such as typhoid fever and meningitis[1].
  • Antibiotic Resistance: The growing concern about antibiotic-resistant bacteria has renewed the focus on broad-spectrum antibiotics like chloramphenicol[1].
  • Affordable Treatment Options: In emerging markets, the demand for cost-effective antibiotics is high, making chloramphenicol a preferred choice[1].

Investment Opportunities

  • Generic Drug Manufacturing: There is significant potential for generic drug manufacturers to invest in chloramphenicol production, especially in countries with high healthcare costs[1].
  • R&D for Improved Formulations: Investing in research and development to enhance the safety profile of chloramphenicol can boost its adoption in developed markets. Innovations in drug delivery systems and nanotechnology are expected to improve its efficacy and safety[1].
  • Healthcare Infrastructure: Improving healthcare infrastructure in developing nations will increase the demand for mass treatment options, including chloramphenicol, in public health initiatives[1].

Challenges

  • Safety Concerns: Chloramphenicol's severe side effects, such as bone marrow suppression, have limited its use in many developed countries. It is often considered a second-line treatment[1].
  • Regulatory Restrictions: Stringent regulatory policies in regions like Europe and North America pose significant hurdles for the market growth of chloramphenicol[1].

Regional Growth

The Asia-Pacific region is leading the growth in the chloramphenicol market due to its high population density and the prevalence of infectious diseases. Africa and Latin America are also expected to contribute significantly to market expansion[1].

Prednisolone Market Dynamics

Market Growth Drivers

The prednisolone market is projected to experience substantial growth driven by:

  • Increasing Prevalence of Chronic Diseases: The rising incidence of chronic diseases such as asthma, allergies, and autoimmune disorders is a primary driver. These conditions necessitate effective treatment options, and prednisolone is a widely used steroid for such conditions[2][5].
  • Advancements in Pharmaceutical Research: Innovations in drug formulations, including extended-release and combination therapies, are enhancing the efficacy of prednisolone. New delivery systems like inhalers and injectables are also contributing to market growth[2].
  • Improved Access to Healthcare: Greater awareness about the benefits of prednisolone and improved access to healthcare facilities are driving the market expansion[2].

Investment Opportunities

  • Research and Development: Pharmaceutical companies are focusing on expanding their product portfolios to include various formulations of prednisolone, presenting lucrative investment opportunities in R&D[2].
  • Strategic Partnerships: Collaborations between pharmaceutical companies and research institutions are fostering innovation in the prednisolone market, aiming to develop more effective and targeted therapies[2].
  • Mergers and Acquisitions: The trend of mergers and acquisitions is allowing companies to consolidate resources, expand their market presence, and enhance their product offerings[2].

Challenges

  • Competition and Regulatory Environment: The prednisolone market faces competition from other steroids and is subject to regulatory scrutiny. However, ongoing innovations and strategic partnerships are helping to mitigate these challenges[2].

Regional Growth

The North American market is expected to hold a significant share of the prednisolone market, driven by the rising prevalence of asthma and other chronic conditions. The Asia-Pacific region is also anticipated to see notable growth due to the lack of physical activity and the increasing prevalence of kidney disorders[5].

Financial Trajectory for Chloramphenicol

Revenue Projections

The chloramphenicol market is expected to grow significantly over the next five years, driven by the increasing demand in emerging markets. The market is anticipated to expand at a CAGR of 4-6%, with the Asia-Pacific region leading the growth[1].

Investment Potential

Investors looking to capitalize on the growth of healthcare in emerging economies will find opportunities in the chloramphenicol segment. Generic drug manufacturing, R&D for improved formulations, and healthcare infrastructure development are key areas for investment[1].

Financial Trajectory for Prednisolone

Revenue Projections

The global prednisolone market is projected to reach significant value by 2027, driven by the increasing prevalence of chronic diseases and advancements in pharmaceutical research. The market is estimated to grow at a substantial rate, with the North American market holding a significant share[2].

Market Size

The prednisone market, closely related to prednisolone, is estimated to cross USD 9 billion by 2036, expanding at a CAGR of around 5% during the forecast period. This growth is largely driven by the surge in the prevalence of skin diseases and other chronic conditions[5].

Key Takeaways

  • Chloramphenicol: The market is driven by the need for affordable and effective antibiotics in emerging markets, with significant growth potential in the Asia-Pacific region. However, it faces challenges related to safety and regulatory restrictions.
  • Prednisolone: The market is driven by the increasing prevalence of chronic diseases and advancements in pharmaceutical research. Strategic partnerships and innovations in drug formulations are key drivers of growth.

FAQs

What are the primary drivers of the chloramphenicol market?

The primary drivers include the increasing prevalence of bacterial infections, concerns about antibiotic resistance, and the demand for cost-effective antibiotics in emerging markets.

What are the main challenges facing the chloramphenicol market?

The main challenges include safety concerns such as bone marrow suppression and stringent regulatory policies in some regions.

Why is the prednisolone market growing?

The prednisolone market is growing due to the increasing prevalence of chronic diseases, advancements in pharmaceutical research, and improved access to healthcare facilities.

What are the key investment opportunities in the prednisolone market?

Key investment opportunities include research and development, strategic partnerships with research institutions, and mergers and acquisitions to expand market presence.

Which regions are leading the growth in the chloramphenicol and prednisolone markets?

The Asia-Pacific region is leading the growth in the chloramphenicol market, while the North American market is significant for prednisolone, driven by the prevalence of chronic diseases like asthma.

Sources

  1. Market Research Intellect: Innovations in Antibiotics Fuel Chloramphenicol Market Growth - A Pharma Sector Insight.
  2. Market Research Intellect: Prednisolone Market Trends - Navigating Growth in the Pharma Sector.
  3. American Society of Tropical Medicine and Hygiene: Abstract Book - Abstracts 7501-8000.
  4. 6Wresearch: North America Chloramphenicol Market (2024-2030).
  5. Research Nester: Prednisone Market Size & Share, Growth Forecasts 2036.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.